Christopher L. Cooper, Sina Bavari
While several impeding factors have limited Ebola vaccine development, the current epidemic has provided a surge which may lead to a record pace for a vaccine against Ebola. Consequently, multiple FDA trials are currently underway using two promising vaccine platforms; one has recently demonstrated durable immunity within non-human primates.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados